Alentis Therapeutics raises USD 181.4M to develop new cancer and fibrosis treatments

Alentis Therapeutics has raised USD 181.4 M in an oversubscribed Series D financing round, aimed at advancing its pipeline of therapies targeting Claudin-1 (CLDN1) for certain cancers and organ fibrosis. The funding will support Alentis as it moves these treatments into clinical trials, addressing critical needs in oncology and fibrotic diseases.

Alentis Therapeutics, a biotech company working on treatments for specific types of tumors and organ fibrosis, has raised USD 181.4M in Series  D funding. This new funding will help Alentis advance its research and development of medicines that target tumors with a protein called Claudin-1 (CLDN1), commonly linked to certain cancers and fibrosis.

The investment round was led by OrbiMed, with Novo Holdings and Jeito Capital also playing major roles. Additional backing came from Frazier Life Sciences, Longitude Capital, Catalio Capital, Piper Heartland Healthcare Capital, and Avego Bioscience Capital. Key existing investors, including RA Capital Management and Morningside Venture Investments, also contributed.

With this funding, Alentis plans to launch clinical trials for two innovative drug candidates, ALE.P02 and ALE.P03, both designed to target CLDN1. The FDA recently approved Alentis to start a clinical trial in early 2025 for ALE.P02, aimed at treating advanced or metastatic CLDN1+ tumors. Another trial for ALE.P03, focusing on CLDN1+ tumors, is also set to begin in 2025.

   Alentis Therapeutics participated in Venture Leaders Biotech in 2022 and was ranked among the TOP 100 Swiss Startups from 2021 to 2023.


Alentis' team from up left to down right: Roberto Iacone (CEO), Luigi Manenti (Chief Medical Officer), Jon Freve (CFO), Rizwan Velji (Chief Business Officer), Alberto Toso (CSO), Valentina Aureggi (SVP BD & Strategic Partnerships), Geoffrey Teixeira (SVP Head Fibrosis), Thomas Baumert (Founder), Markus Meyer (COO), and Nathalie Graf (Head of CEO & Management Support)